➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Colorcon
Express Scripts
Harvard Business School
McKinsey

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

IMIPRAMINE PAMOATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Imipramine Pamoate patents expire, and what generic alternatives are available?

Imipramine Pamoate is a drug marketed by Hikma, Lupin Ltd, and Mylan Pharms Inc. and is included in three NDAs.

The generic ingredient in IMIPRAMINE PAMOATE is imipramine pamoate. There are thirty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the imipramine pamoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Imipramine Pamoate

A generic version of IMIPRAMINE PAMOATE was approved as imipramine pamoate by HIKMA on April 16th, 2010.

  Get Started for $10

Summary for IMIPRAMINE PAMOATE
Drug patent expirations by year for IMIPRAMINE PAMOATE
Drug Prices for IMIPRAMINE PAMOATE

See drug prices for IMIPRAMINE PAMOATE

Recent Clinical Trials for IMIPRAMINE PAMOATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shalvata Mental Health CenterN/A
Roxane LaboratoriesN/A

See all IMIPRAMINE PAMOATE clinical trials

Pharmacology for IMIPRAMINE PAMOATE

US Patents and Regulatory Information for IMIPRAMINE PAMOATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma IMIPRAMINE PAMOATE imipramine pamoate CAPSULE;ORAL 091099-001 Apr 16, 2010 AB RX No Yes   Get Started for $10   Get Started for $10   Get Started for $10
Lupin Ltd IMIPRAMINE PAMOATE imipramine pamoate CAPSULE;ORAL 090444-003 Apr 16, 2010 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Hikma IMIPRAMINE PAMOATE imipramine pamoate CAPSULE;ORAL 091099-004 Apr 16, 2010 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Mylan Pharms Inc IMIPRAMINE PAMOATE imipramine pamoate CAPSULE;ORAL 202338-004 Jun 28, 2013 DISCN No No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Moodys
Harvard Business School
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.